CD36 and metabolic dysfunction-associated steatotic liver disease: Given that CD36’s palmitoylation status is associated with disrupted fatty acid metabolism and tissue inflammation, inhibiting CD36 palmitoylation could represent a potential treatment strategy for NAFLD (Maréchal et al., 2018; Ding et al., 2019; Zhao et al., 2022).